Judge Kavanaugh May Be Good US Supreme Court Pick For Pharma
Supreme Court nominee may side with biopharma companies in agency disputes, but it's unclear how he will rule on patent and product liability cases scheduled for review next term.
You may also be interested in...
Product Liability Returning To Supreme Court With Government, Former FDA Officials On Opposite Sides
But Patent Trial and Appeals Board must issue final written decision on all claims raised by challenger – not just some of them, court says; rulings in two closely watched cases mean that IPR proceedings can continue unabated, but generic drug and biosimilar sponsors may need to rethink how they go about challenging innovator patent claims.